Novo Nordisk aims for market domination, boasts $1.5bn obesity sales in Q1
Novo Nordisk noted a 22% boost in sales owing to increased sales of GLP-1 agonists and other obesity products.
Novo Nordisk noted a 22% boost in sales owing to increased sales of GLP-1 agonists and other obesity products.
What's Your Reaction?
